Sands BE

No ORCID on file · 2 papers in corpus

2024

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.

Inflammatory bowel diseases ·doi:10.1093/ibd/izae024

BackgroundMirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative col…

article 2014

Menstrual Cycle Changes in Women with Inflammatory Bowel Disease

Inflammatory bowel diseases ·doi:10.1097/01.mib.0000441347.94451.cf

BACKGROUND: The effect of the inflammatory bowel diseases (IBD) on menstrual function is largely unknown. The aims of this study were to determine whether changes in menstrual function occur in the year before IBD diagnosis or in the initia…